Johnson & Johnson at outperform by RBC

RBC Capital Markets analyst Phi Nalbone gave Johnson & Johnson a rating of outperform, average risk, after the company announced a definitive agreement to purchase Pfizer Consumer Healthcare for $16.6 billion. The company plans to finance the transaction with existing cash on hand. The analyst raised its 2007 sales estimate by $4.4 billion to $60.82 billion and lowered its 2007 earnings-per-share estimate by 12 cents to $3.86. Shares of the New Brunswick, N.J.-based pharmaceutical company were down 66 cents, or 1.10%, at $59.55 on volume of 10,336,600 shares versus the three-month running average of 8,873,270 shares. (NYSE: JNJ)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.